Horizon Therapeutics (HZNP) Tops Q2 EPS by 4c on Revenue Blowout, Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Horizon Therapeutics (HZNP) PT Raised to $100 at Cowen
August 5, 2020 10:31 AM EDTCowen analyst Ken Cacciatore raised the price target on Horizon Therapeutics (NASDAQ: HZNP) to $100.00 (from $80.00) while maintaining a Outperform rating following results.
The analyst commented, "Tepezza results were stunning, and importantly, management's commentary matches our clinician checks, with the solid efficacy/safety... More
